Free Trial
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free DNA Stock Alerts

Ginkgo Bioworks (DNA) Competitors

Ginkgo Bioworks logo
$9.59 -0.32 (-3.23%)
As of 03:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

DNA vs. TWST, HCM, ADPT, SRPT, and PAHC

Should you be buying Ginkgo Bioworks stock or one of its competitors? The main competitors of Ginkgo Bioworks include Twist Bioscience (TWST), HUTCHMED (HCM), Adaptive Biotechnologies (ADPT), Sarepta Therapeutics (SRPT), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical products" industry.

How does Ginkgo Bioworks compare to Twist Bioscience?

Twist Bioscience (NASDAQ:TWST) and Ginkgo Bioworks (NYSE:DNA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

In the previous week, Twist Bioscience had 20 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 23 mentions for Twist Bioscience and 3 mentions for Ginkgo Bioworks. Twist Bioscience's average media sentiment score of 0.05 beat Ginkgo Bioworks' score of 0.00 indicating that Twist Bioscience is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Twist Bioscience
6 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Neutral
Ginkgo Bioworks
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Twist Bioscience has a net margin of -19.56% compared to Ginkgo Bioworks' net margin of -183.81%. Twist Bioscience's return on equity of -27.16% beat Ginkgo Bioworks' return on equity.

Company Net Margins Return on Equity Return on Assets
Twist Bioscience-19.56% -27.16% -19.92%
Ginkgo Bioworks -183.81%-52.82%-25.45%

78.6% of Ginkgo Bioworks shares are owned by institutional investors. 3.1% of Twist Bioscience shares are owned by insiders. Comparatively, 9.7% of Ginkgo Bioworks shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Twist Bioscience has higher revenue and earnings than Ginkgo Bioworks. Twist Bioscience is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Twist Bioscience$391.56M8.81-$77.67M-$1.33N/A
Ginkgo Bioworks$170.15M3.49-$312.76M-$5.65N/A

Twist Bioscience has a beta of 2.22, indicating that its share price is 122% more volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500.

Twist Bioscience currently has a consensus price target of $53.00, indicating a potential downside of 5.82%. Ginkgo Bioworks has a consensus price target of $8.50, indicating a potential downside of 11.37%. Given Twist Bioscience's stronger consensus rating and higher probable upside, equities research analysts plainly believe Twist Bioscience is more favorable than Ginkgo Bioworks.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Twist Bioscience
2 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.60
Ginkgo Bioworks
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67

Summary

Twist Bioscience beats Ginkgo Bioworks on 13 of the 16 factors compared between the two stocks.

How does Ginkgo Bioworks compare to HUTCHMED?

Ginkgo Bioworks (NYSE:DNA) and HUTCHMED (NASDAQ:HCM) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

In the previous week, Ginkgo Bioworks and Ginkgo Bioworks both had 3 articles in the media. HUTCHMED's average media sentiment score of 0.02 beat Ginkgo Bioworks' score of 0.00 indicating that HUTCHMED is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ginkgo Bioworks
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
HUTCHMED
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

78.6% of Ginkgo Bioworks shares are owned by institutional investors. Comparatively, 8.8% of HUTCHMED shares are owned by institutional investors. 9.7% of Ginkgo Bioworks shares are owned by company insiders. Comparatively, 3.6% of HUTCHMED shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Ginkgo Bioworks presently has a consensus price target of $8.50, indicating a potential downside of 11.37%. HUTCHMED has a consensus price target of $16.88, indicating a potential upside of 28.37%. Given HUTCHMED's stronger consensus rating and higher possible upside, analysts plainly believe HUTCHMED is more favorable than Ginkgo Bioworks.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ginkgo Bioworks
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67
HUTCHMED
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.33

HUTCHMED has higher revenue and earnings than Ginkgo Bioworks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ginkgo Bioworks$170.15M3.49-$312.76M-$5.65N/A
HUTCHMED$548.51M4.18$456.91MN/AN/A

HUTCHMED has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -183.81%. HUTCHMED's return on equity of 0.00% beat Ginkgo Bioworks' return on equity.

Company Net Margins Return on Equity Return on Assets
Ginkgo Bioworks-183.81% -52.82% -25.45%
HUTCHMED N/A N/A N/A

Ginkgo Bioworks has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500.

Summary

HUTCHMED beats Ginkgo Bioworks on 10 of the 13 factors compared between the two stocks.

How does Ginkgo Bioworks compare to Adaptive Biotechnologies?

Adaptive Biotechnologies (NASDAQ:ADPT) and Ginkgo Bioworks (NYSE:DNA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

In the previous week, Adaptive Biotechnologies had 3 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 6 mentions for Adaptive Biotechnologies and 3 mentions for Ginkgo Bioworks. Adaptive Biotechnologies' average media sentiment score of 0.74 beat Ginkgo Bioworks' score of 0.00 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Adaptive Biotechnologies
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ginkgo Bioworks
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Adaptive Biotechnologies has higher revenue and earnings than Ginkgo Bioworks. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adaptive Biotechnologies$276.98M8.03-$59.50M-$0.40N/A
Ginkgo Bioworks$170.15M3.49-$312.76M-$5.65N/A

Adaptive Biotechnologies has a net margin of -21.48% compared to Ginkgo Bioworks' net margin of -183.81%. Adaptive Biotechnologies' return on equity of -46.68% beat Ginkgo Bioworks' return on equity.

Company Net Margins Return on Equity Return on Assets
Adaptive Biotechnologies-21.48% -46.68% -18.55%
Ginkgo Bioworks -183.81%-52.82%-25.45%

99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 6.4% of Adaptive Biotechnologies shares are held by insiders. Comparatively, 9.7% of Ginkgo Bioworks shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Adaptive Biotechnologies has a beta of 2.16, meaning that its share price is 116% more volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500.

Adaptive Biotechnologies presently has a consensus target price of $19.43, indicating a potential upside of 39.64%. Ginkgo Bioworks has a consensus target price of $8.50, indicating a potential downside of 11.37%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, equities analysts clearly believe Adaptive Biotechnologies is more favorable than Ginkgo Bioworks.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adaptive Biotechnologies
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
Ginkgo Bioworks
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67

Summary

Adaptive Biotechnologies beats Ginkgo Bioworks on 14 of the 16 factors compared between the two stocks.

How does Ginkgo Bioworks compare to Sarepta Therapeutics?

Sarepta Therapeutics (NASDAQ:SRPT) and Ginkgo Bioworks (NYSE:DNA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

In the previous week, Sarepta Therapeutics and Sarepta Therapeutics both had 3 articles in the media. Sarepta Therapeutics' average media sentiment score of 0.80 beat Ginkgo Bioworks' score of 0.00 indicating that Sarepta Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sarepta Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ginkgo Bioworks
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Sarepta Therapeutics has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500.

Ginkgo Bioworks has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sarepta Therapeutics$2.20B1.03-$713.41M-$8.44N/A
Ginkgo Bioworks$170.15M3.49-$312.76M-$5.65N/A

Sarepta Therapeutics has a net margin of -38.34% compared to Ginkgo Bioworks' net margin of -183.81%. Sarepta Therapeutics' return on equity of -50.74% beat Ginkgo Bioworks' return on equity.

Company Net Margins Return on Equity Return on Assets
Sarepta Therapeutics-38.34% -50.74% -18.00%
Ginkgo Bioworks -183.81%-52.82%-25.45%

86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are owned by institutional investors. 6.9% of Sarepta Therapeutics shares are owned by company insiders. Comparatively, 9.7% of Ginkgo Bioworks shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Sarepta Therapeutics presently has a consensus target price of $32.63, suggesting a potential upside of 52.57%. Ginkgo Bioworks has a consensus target price of $8.50, suggesting a potential downside of 11.37%. Given Sarepta Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Sarepta Therapeutics is more favorable than Ginkgo Bioworks.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sarepta Therapeutics
6 Sell rating(s)
13 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.11
Ginkgo Bioworks
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67

Summary

Sarepta Therapeutics beats Ginkgo Bioworks on 9 of the 15 factors compared between the two stocks.

How does Ginkgo Bioworks compare to Phibro Animal Health?

Ginkgo Bioworks (NYSE:DNA) and Phibro Animal Health (NASDAQ:PAHC) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

Ginkgo Bioworks presently has a consensus target price of $8.50, suggesting a potential downside of 11.37%. Phibro Animal Health has a consensus target price of $42.40, suggesting a potential downside of 25.37%. Given Ginkgo Bioworks' higher probable upside, equities analysts plainly believe Ginkgo Bioworks is more favorable than Phibro Animal Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ginkgo Bioworks
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67
Phibro Animal Health
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.43

Phibro Animal Health has higher revenue and earnings than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ginkgo Bioworks$170.15M3.49-$312.76M-$5.65N/A
Phibro Animal Health$1.46B1.57$48.26M$2.2525.25

In the previous week, Phibro Animal Health had 9 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 12 mentions for Phibro Animal Health and 3 mentions for Ginkgo Bioworks. Phibro Animal Health's average media sentiment score of 0.42 beat Ginkgo Bioworks' score of 0.00 indicating that Phibro Animal Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ginkgo Bioworks
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Phibro Animal Health
4 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

78.6% of Ginkgo Bioworks shares are owned by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are owned by institutional investors. 9.7% of Ginkgo Bioworks shares are owned by insiders. Comparatively, 50.1% of Phibro Animal Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Ginkgo Bioworks has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.

Phibro Animal Health has a net margin of 6.29% compared to Ginkgo Bioworks' net margin of -183.81%. Phibro Animal Health's return on equity of 38.28% beat Ginkgo Bioworks' return on equity.

Company Net Margins Return on Equity Return on Assets
Ginkgo Bioworks-183.81% -52.82% -25.45%
Phibro Animal Health 6.29%38.28%8.37%

Summary

Phibro Animal Health beats Ginkgo Bioworks on 14 of the 17 factors compared between the two stocks.

Get Ginkgo Bioworks News Delivered to You Automatically

Sign up to receive the latest news and ratings for DNA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DNA vs. The Competition

Export
MetricGinkgo BioworksMED IndustryMedical SectorNYSE Exchange
Market Cap$595.42M$3.39B$6.25B$23.00B
Dividend YieldN/A2.20%2.73%4.03%
P/E Ratio-1.7038.9029.0628.59
Price / Sales3.49159.23475.7523.63
Price / CashN/A57.8827.6219.03
Price / Book1.107.039.714.69
Net Income-$312.76M$23.62M$3.55B$1.07B
7 Day Performance21.84%3.52%1.65%0.97%
1 Month Performance38.28%7.03%5.54%6.63%
1 Year Performance38.68%66.41%34.16%31.82%

Ginkgo Bioworks Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DNA
Ginkgo Bioworks
0.5331 of 5 stars		$9.59
-3.2%		$8.50
-11.4%		N/A$595.42M$170.15MN/A640
TWST
Twist Bioscience
1.2043 of 5 stars		$56.19
-7.0%		$48.38
-13.9%		N/A$3.70B$376.57MN/A990
HCM
HUTCHMED
2.8518 of 5 stars		$13.22
-0.6%		$16.88
+27.6%		N/A$2.32B$548.51MN/A1,796
ADPT
Adaptive Biotechnologies
3.3348 of 5 stars		$14.50
+1.6%		$19.43
+34.0%		N/A$2.28B$276.98MN/A790
SRPT
Sarepta Therapeutics
3.1875 of 5 stars		$22.04
+2.6%		$32.63
+48.0%		N/A$2.27B$2.20BN/A1,372

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:DNA) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel